Spastic Paraplegia 21 (SPG21) (C-Term) Peptide
Quick Overview for Spastic Paraplegia 21 (SPG21) (C-Term) Peptide (ABIN1541417)
Target
Origin
Source
Application
-
-
Protein Region
- C-Term
-
Sequence
- IPVTIMDVFD QSALSTEAKE EMYKLYPNAR RAHLKTGGNF PYLCRSAEVN
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti-SPG21 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SPG21 (Spastic Paraplegia 21 (SPG21))
-
Background
-
The protein encoded by this gene was identified by a two-hybrid screen using CD4 as the bait. It binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. At least three different transcript variants encoding two different isoforms have been found for this gene.
Alias Symbols: ACP33, BM-019, GL010, MASPARDIN, MAST
Protein Size: 308 -
Molecular Weight
- 35 kDa
-
Gene ID
- 51324
-
NCBI Accession
- NM_016630, NP_057714
-
UniProt
- Q9NZD8
Target
-